Epstein-Barr virus immediate-early protein BZLF1 (BZLF1)

The Epstein-Barr virus (EBV) immediate-early protein BZLF1, also known as Zta or ZEBRA, is a master regulatory transcription factor that serves as the molecular switch for transitioning the virus from its latent state to the lytic replication phase [1, 5]. As a member of the basic leucine zipper (bZIP) family, BZLF1 homodimerizes to bind specific DNA sequences known as Z-response elements (ZREs), with a unique preference for methylated CpG motifs that typically silence the viral genome [1, 4]. Its expression initiates a cascade of viral gene activation, including the induction of the early gene BRLF1 and the recruitment of the viral replication machinery to the lytic origin of replication (oriLyt) [1, 5, 15]. BZLF1 also modulates the host environment by inducing G1 cell cycle arrest and suppressing immune signaling pathways like p53 and TNF [13, 16]. In oncology, BZLF1 is a pivotal target for "lytic induction therapy" (or cytolytic virus activation), where pharmacological agents such as HDAC inhibitors (e.g., romidepsin, valproic acid) or certain chemotherapies (e.g., gemcitabine) are used to induce its expression in EBV-positive tumor cells [9, 11, 15]. This reactivation makes the cells susceptible to antiviral prodrugs like ganciclovir, which are converted into lethal metabolites by viral kinases (e.g., BGLF4) induced during the BZLF1-triggered lytic cycle [10, 12, 15]. Beyond its role in lytic induction, BZLF1 is being investigated as a target for T-cell-based immunotherapies and as a candidate antigen for preventive and therapeutic EBV vaccines [6, 7].

Other names

ZtaZEB1ZEBRAZ transactivatorBamHI Z fragment leftward open reading frame 1 proteinLytic switch protein BZLF1

Therapeutic strategies involve lytic induction (cytolytic virus activation) where pharmacological agents (e.g., HDAC inhibitors or chemotherapy) induce BZLF1 expression to trigger the viral lytic cycle; this cycle expresses viral kinases (e.g., BGLF4) that phosphorylate co-administered antiviral prodrugs (e.g., ganciclovir) into cytotoxic metabolites, selectively killing the EBV-infected tumor cells.